2016 Atrial Fibrillation Heart Failure 
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%
Journal of the American Heart Association
MARCH 27, 2025
years]) admitted to the China Chest Pain Center Database between 2016 and 2021. Hierarchical clustering of 15 medical conditions was performed to derive multimorbidity patterns. The primary outcome was a composite of inhospital adverse events.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
from 2016‐2019 and secondary diagnosis of T2DM. Data was weighted to allow for representative nationwide estimates.ResultsWe identified 426,549 patients who were admitted with a primary diagnosis of TIA between 2016 and 2019. The primary diagnosis of the readmission was used to identify the etiology of readmission.
Journal of Cardiovascular Electrophysiology
MARCH 11, 2025
Methods A retrospective cohort analysis was conducted using the National Readmissions Database (NRD) from 2016 to 2021. Urban hospital patients had a higher prevalence of key comorbidities, including heart failure, valvular heart disease, atrial fibrillation and peripheral vascular disorders.
DAIC
JULY 24, 2024
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrial fibrillation procedures. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
Frontiers in Cardiovascular Medicine
FEBRUARY 14, 2024
Background The impact of early rhythm control (ERC) combined with healthy lifestyle (HLS) on the risk of ischemic stroke in elderly patients with atrial fibrillation (AF) remains unaddressed. Objective To evaluate the impact of combined ERC and HLS on the risk of stroke in elderly patients with new-onset AF.
DAIC
JUNE 19, 2024
In July 2023 Eko Health announced a partnership with Japanese Life Sciences company Astellas Pharma to develop a non-invasive device Digital Therapeutics (DTx) solution for heart failure patients. In April 2022 BMS had received FDA approval for Camzyos, the first drug developed specifically for targeting HCM.
Expert insights. Personalized for you.
40 
Let's personalize your content